- Home
- TDF vs NNNN Comparison
TDF vs NNNN Comparison
Compare TDF & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- NNNN
- Stock Information
- Founded
- TDF 1994
- NNNN 2021
- Country
- TDF Singapore
- NNNN Germany
- Employees
- TDF N/A
- NNNN N/A
- Industry
- TDF Finance/Investors Services
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TDF Finance
- NNNN Health Care
- Exchange
- TDF Nasdaq
- NNNN Nasdaq
- Market Cap
- TDF 244.7M
- NNNN 267.7M
- IPO Year
- TDF N/A
- NNNN 2025
- Fundamental
- Price
- TDF $9.47
- NNNN $7.87
- Analyst Decision
- TDF
- NNNN
- Analyst Count
- TDF 0
- NNNN 0
- Target Price
- TDF N/A
- NNNN N/A
- AVG Volume (30 Days)
- TDF 79.2K
- NNNN 44.5K
- Earning Date
- TDF 01-01-0001
- NNNN 01-01-0001
- Dividend Yield
- TDF N/A
- NNNN N/A
- EPS Growth
- TDF N/A
- NNNN N/A
- EPS
- TDF N/A
- NNNN 0.06
- Revenue
- TDF N/A
- NNNN $8,185,146.00
- Revenue This Year
- TDF N/A
- NNNN N/A
- Revenue Next Year
- TDF N/A
- NNNN N/A
- P/E Ratio
- TDF N/A
- NNNN $140.27
- Revenue Growth
- TDF N/A
- NNNN 21.95
- 52 Week Low
- TDF $7.15
- NNNN $5.18
- 52 Week High
- TDF $10.62
- NNNN $8.22
- Technical
- Relative Strength Index (RSI)
- TDF 48.70
- NNNN N/A
- Support Level
- TDF $9.48
- NNNN N/A
- Resistance Level
- TDF $9.70
- NNNN N/A
- Average True Range (ATR)
- TDF 0.13
- NNNN 0.00
- MACD
- TDF -0.02
- NNNN 0.00
- Stochastic Oscillator
- TDF 6.67
- NNNN 0.00
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.